Finance

Lists
TMDX:NASDAQ
TransMedics Group Inc
$83.81
-1.74%
(-1.48) 1D
Sep 28, 12:05:47 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TMDX...
Open
$86.38
High
$86.38
Low
$83.33
Mkt. cap
2.91B
Avg. vol.
698.66K
Volume
96.51K
P/E ratio
21.80
52-wk high
$156.00
52-wk low
$60.10
EPS
$3.84
Beta
1.90
Shares outstanding
34.68M
No. of employees
898
Open
$86.38
High
$86.38
Low
$83.33
Mkt. cap
2.91B
Avg. vol.
698.66K
Volume
96.51K
P/E ratio
21.80
52-wk high
$156.00
52-wk low
$60.10
EPS
$3.84
Beta
1.90
Shares outstanding
34.68M
No. of employees
898
News stories
From web sources and news partners
About TransMedics Group Inc
CEO-
Employees898
Founded1998
HeadquartersAndover, Massachusetts, United States
SectorMedical device
Websitetransmedics.com
Analyst ratings
Based on 11 analysts giving stock ratings to TMDX in the past 3 months
Buy
Buy
7
Hold
4
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for TMDX in the last 3 months.
Highest
Current $83.81
$122.00 (+45.57%)
Average
$94.22 (+12.42%)
Lowest
$65.00 (-22.44%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Matson
Needham
Buy
Reiterated
$106.00
+26.5%
09/22/2026
Thomas Stephan
Stifel Nicolaus
Hold
Maintained
$65.00
-22.4%
09/11/2026
Matthew O'Brien
Piper Sandler
Buy
Maintained
$100.00
+19.3%
09/11/2026
William Plovanic
Canaccord Genuity
Buy
Maintained
$95.00
+13.4%
09/11/2026
Ryan Daniels
William Blair
Buy
Maintained
-
-
09/10/2026
Josh Jennings
TD Cowen
Buy
Reiterated
$120.00
+43.2%
09/08/2026
Suraj Kalia
Oppenheimer
Hold
Maintained
-
-
08/24/2026
Allen Gong
J.P. Morgan
Hold
Maintained
$73.00
-12.9%
08/06/2026
Patrick Wood
UBS
Hold
Reiterated
$77.00
-8.1%
08/05/2026
David Rescott
Robert W. Baird
Buy
Maintained
$122.00
+45.6%
08/05/2026
Unknown Analyst
UBS
Hold
Initiated
$80.00
-4.5%
07/28/2026
Daniel Markowitz CFA
Evercore ISI
Buy
Maintained
$90.00
+7.4%
07/06/2026
Rob Owens
Piper Sandler
Hold
Reiterated
$63.00
-24.8%
06/02/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
143.82M
160.76M
173.93M
189.95M
Cost of goods sold
59.25M
67.35M
72.77M
76.75M
Cost of revenue
59.25M
67.35M
72.77M
76.75M
Research and development expenses
15.26M
20.70M
24.88M
31.63M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
46.02M
51.44M
62.98M
57.83M
Operating expense
61.28M
72.14M
87.86M
89.46M
Total operating expenses
120.52M
139.49M
160.64M
166.21M
Operating income
23.30M
21.27M
13.30M
23.74M
Other non operating income
22.00K
2.41M
258.00K
-6.00K
EBT including unusual items
23.03M
21.63M
8.48M
19.40M
EBT excluding unusual items
23.03M
21.63M
8.48M
19.40M
Income tax expense
-1.29M
-83.75M
1.17M
4.72M
Effective tax rate
-5.59%
-387.14%
13.79%
24.34%
Other operating expenses
-
-
-
-
Net income
24.32M
105.38M
7.32M
14.68M
Net profit margin
16.91%
65.55%
4.21%
7.73%
Earnings per share
0.66
0.53
0.30
0.44
Interest and investment income
3.30M
3.30M
2.70M
3.00M
Interest expense
-3.49M
-3.35M
-7.17M
-7.22M
Net interest expenses
-191.00K
-54.00K
-4.47M
-4.22M
Depreciation and amortization charges
-
-
-
-
EBITDA
29.35M
28.24M
24.46M
33.18M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps